TORONTO, April 07, 2025--(BUSINESS WIRE)--Predictmedix AI Inc. (CSE: PMED) (OTC: PMEDF) (FRA: 3QP) ("Predictmedix" or the "Company"), a leading provider in AI-driven health and safety solutions, proudly announces a significant milestone: its Smart Health AI Stations have successfully completed over 500,000 individual scans. This achievement highlights the scalability, precision, and real-world impact of Predictmedix AI’s cutting-edge machine learning technology, transforming health and safety standards across healthcare, corporate, and public sectors.
Scalable Innovation Driving Change
The completion of 500,000 scans showcases the power of Predictmedix AI’s non-invasive, AI-powered screening tools, designed to deliver unmatched accuracy and efficiency. By integrating advanced computer vision with adaptive machine learning, the Smart Health AI Stations detect critical health risks—including infectious disease symptoms, mental health indicators, and impairment—in real time. With every scan, the system’s algorithms become sharper, enabling faster, more reliable interventions and fostering safer environments for organizations and communities worldwide.
Empowering Health and Well-Being
"Reaching 500,000 scans is more than a technological triumph—it’s a testament to the trust we’ve earned and the lives we’re helping protect," said Dr. Rahul Kushwah, Chief Operating Officer of Predictmedix AI. "Our Smart Health AI Stations harness vast datasets to refine diagnostic precision, giving organizations the insights they need to act swiftly. As we push the boundaries of machine learning, we’re expanding our focus to address both physical and mental well-being, ensuring our solutions remain vital in today’s evolving health and safety landscape."
Versatile Solutions for a Modern World
From rapid vitals screening to impairment detection, Predictmedix AI’s technology offers privacy-focused, actionable health insights with minimal disruption. Its growing mental health assessment capabilities are proving especially valuable, enabling employers to identify stress, fatigue —supporting employee well-being through proactive, data-driven care. This versatility makes the Smart Health AI Stations a game-changer across industries.
Looking Ahead
With this milestone, Predictmedix AI solidifies its position as a leader in AI-powered health innovation. The company is poised for continued growth, with plans to strengthen industry partnerships, integrate multimodal health data, and explore new frontiers in telemedicine and personalized analytics. As the demand surges for ethical, automated AI solutions, Predictmedix AI remains committed to advancing tools that prioritize safety, health, and well-being on a global scale.
Predictmedix AI Inc. (CSE: PMED) (OTC: PMEDF) (FRA:3QP) is an emerging provider of rapid health screening and remote patient care solutions globally. The Company’s Safe Entry Stations – powered by a proprietary artificial intelligence (AI) – use multispectral cameras to analyze physiological data patterns and predict a variety of health issues including 19 physiological vital parameters, impairment by drugs or alcohol, fatigue, or various mental illnesses. Predictmedix AI’s proprietary remote patient care platform empowers medical professionals with a suite of AI-powered tools to improve patient health outcomes. To learn more, please visit our website at www.Predictmedix.com or follow us on Twitter, Instagram or LinkedIn.
Caution Regarding Forward-Looking Information:
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company’s securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company’s actual results, performance or achievements to be materially different from any Page 4 of 4 future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the Company, including risks related to COVID-19; risks related to the Company’s shares, including price volatility due to events that may or may not be within such party’s control; reliance on management; and the emergency of additional competitors in the industry.
All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law.
Disclaimer: The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time.
THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
